

PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

Manuscript NO: 46796

Title: Pharmacologic adjunctive to insulin therapies in type 1 diabetes: The journey has just begun

Reviewer's code: 00058696

Reviewer's country: United States

Science editor: Fang-Fang Ji

Reviewer accepted review: 2019-02-26 14:54

Reviewer performed review: 2019-03-06 21:05

Review time: 8 Days and 6 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input checked="" type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

I have carefully read this new manuscript. My major questions are summarized below: 1) In the title, do the authors mean "Pharmacologic Adjunctive Therapy to Insulin ..."? Otherwise, there need to be sections added discussing weight loss &



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

bariatric surgery and diet & activity programs. 2) In “Why is There a Need...”, can the authors add a description of the problems with the cost of and the availability of insulin for treatment of patients with Type 1 Diabetes? 3) In “An Overview of Available Evidence”, can the authors summarize pertinent studies in a Table? 4) In “A Critical Appraisal of Relevant Studies”, can the authors summarize identified limitations in a Table? 5) It would be helpful if the authors had a Section more clearly labeled as “Future Clinical Research Studies”. This topic is the last sentence in the authors’ Abstract, but it is not clearly brought out in their present manuscript.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ [Y] No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ [Y] No